VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IART
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IARTIntegra LifeSciences Holdings Corporation
$13.55$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
IART logo

Integra LifeSciences Holdings Corporation

IART
NASDAQ · Medical Devices
$13.55
At close - Nov 17, 4:00 PM EST - USD
Market Cap$1.05B
P/E81.8x
52W High$20.49
Volume1.17M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Impairment Aftermath Leaves Integra Structurally Fragile

Integra LifeSciences' post-2025 baseline shows revenue growth decelerating to 2.3% in Q3 2026 from 11.5% in Q4 2024, with gross margins swinging as widely as 49.5% to 57.2% over ten quarters, suggesting manufacturing remediation costs in Tissue Reconstruction may be structural rather than transitory.

GrowthDecelerating
ProfitabilityStrained
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

IART price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

+208% Peers

P/E is 208% above peer median

03

Market leadership

RS 55 · Avg

Average momentum (RS Rating: 55)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Jan 21

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
IART+12.82%
S&P 500 (^GSPC)+7.21%
1-Year Return
IART+15.52%
S&P 500 (^GSPC)+10.03%
3-Year Return
IART-65.03%
S&P 500 (^GSPC)+60.26%
5-Year Return
IART-80.24%
S&P 500 (^GSPC)+54.55%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
83.7x
Forward P/EExpansion
5.9x
EV/EBITDA0th %ile
3.7x
FCF YieldCash Flow
9.2%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
83.7x
33.8x
100th· High
EV/EBITDA
3.7x
20.6x
0th· Low
Price/FCF
10.9x
47.9x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$63.23+366.6%
Base (Fair)$117.84+718.3%
Bull$189.76+1300.4%
$63.23 Bear$117.84 Base$189.76 Bull
Current Market Price: $13.55
Trades at a 88.5% discount to Base DCF ($117.84)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.64B+1.5% YoY
Net income FY25
-$516M-7337.7% YoY
Free cash flow FY25
-$45M-281.3% YoY
Operating margin FY25
4.2%+2.4 pts YoY
ROIC (FY25)1.7%
Avg ROIC 5Y3.3%
ROE (TTM)1.2%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 21, 2026
$0.59+5.9%
vs $0.56
$411M-0.5%
vs $413M
Q3 2026
Jul 29, 2026
$0.56+16.5%
vs $0.48
$419M+0.3%
vs $418M
Q2 2026
May 5, 2026
$0.54+31.7%
vs $0.41
$392M+2.6%
vs $382M
Q1 2026
Feb 26, 2026
$0.83+5.1%
vs $0.79
$435M+1.2%
vs $430M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 10, 2026
Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript

Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript

GlobeNewsWire·Nov 6, 2026
Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference

PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET.

Seeking Alpha·Oct 23, 2026
Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting

Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.

Business Wire·Oct 23, 2026
Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 2, 2026 disclosure c.

Filtered for Integra LifeSciences Holdings CorporationMore Headlines
04

Compare before deciding

Benchmark IART against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Integra LifeSciences Holdings Corporation (IART)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
IART logoIARTIntegra LifeSciences Holdings CorporationCurrent
$13.55$1.05B81.821.53%0.79%1.24%—
NVCR logoNVCRNovocure Ltd
$11.14$1.29B-10.698.28%-16.78%-35.81%—
ATRC logoATRCAtriCure, Inc.
$55.02$2.8B184.2014.88%2.52%2.93%—
NTRA logoNTRANatera, Inc.
$287.47$41.17B-251.4435.9%-5.66%-9.18%—
MMSI logoMMSIMerit Medical Systems, Inc.
$84.49$5.04B31.8611.66%9.94%9.65%—
LMAT logoLMATLeMaitre Vascular, Inc.
$76.10$1.74B27.7213.53%23.51%15.33%1.04%

Compare IART vs Peers

Integra LifeSciences Holdings Corporation (IART) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for IART.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare IART against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ATRC, NTRA, MMSI

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

IART SEC Filings & Documents

Integra LifeSciences Holdings Corporation (IART) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 21, 2026·SEC

Material company update

Oct 19, 2026·SEC

Material company update

Oct 9, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 25, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 23, 2026·SEC

FY 2026

Jul 29, 2026·SEC

FY 2026

May 5, 2026·SEC

Get notified when IART posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

IART Frequently Asked Questions

Integra LifeSciences Holdings Corporation (IART) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Integra LifeSciences Holdings Corporation's revenue?

Integra LifeSciences Holdings Corporation (IART) reported $1.66B in revenue over the trailing twelve months. Revenue was $1.64B in fiscal year 2025. That is 12383% more than the $13.1M of fiscal year 1996.

How fast is Integra LifeSciences Holdings Corporation growing?

Integra LifeSciences Holdings Corporation (IART) grew revenue by 0.8% over the trailing twelve months, compared with the twelve months before.

Is IART profitable?

Yes. Integra LifeSciences Holdings Corporation (IART) earned $13.0M in net income over the trailing twelve months (a 0.8% net margin).

Dividend & Returns
What is IART's return on equity?

Integra LifeSciences Holdings Corporation (IART) had a return on equity (ROE) of 1.2% over the trailing twelve months. That is below the market's typical 10-15%.

What is Integra LifeSciences Holdings Corporation's free cash flow?

Integra LifeSciences Holdings Corporation (IART) generated $98.7M in free cash flow over the trailing twelve months.

What if you invested $1,000 in IART back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →